TY - JOUR
T1 - Perspectives in engineered mesenchymal stem/stromal cells based anti- cancer drug delivery systems
AU - Ackova, Darinka Gjorgieva
AU - Kanjevac, Tatjana
AU - Rimondini, Lia
AU - Bosnakovski, Darko
N1 - Publisher Copyright:
© 2016 Bentham Science Publishers.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Understanding and apprehension of the characteristics and circumstances in which mesenchymal stem cells (MSCs) affect and make alterations (enhance or reduce) to the growth of tumors and metastasis spread is pivotal, not only for reaching the possibility to employ MSCs as drug delivery systems, but also for making forward movement in the existing knowledge of involvement of major factors (tumor microenvironment, soluble signaling molecules, etc.) in the process of carcinogenesis. This capability is reliable because MSCs present a great basis for engineering and constructions of new systems to target cancers, intended to secrete therapeutic proteins in the tumor region, or for delivering of oncolytic viruses’ directly at the tumor site (targeted chemotherapy with enzyme prodrug conversion or induction of tumor cell apoptosis). MSCs as a crucial segment of the tumor surroundings and their confirmed tumor tropism, are assumed to be an open gateway for the design of promising drug delivery systems. The presented paper reviews current publications in this fieldwork, searches out the most recent patents that were published after 2012 (WO2014066122, US20140017787, WO2015100268, US20150086515), and tries to present the current progress and future prospective on the design and development in anti-cancer drug delivery systems based on MSCs.
AB - Understanding and apprehension of the characteristics and circumstances in which mesenchymal stem cells (MSCs) affect and make alterations (enhance or reduce) to the growth of tumors and metastasis spread is pivotal, not only for reaching the possibility to employ MSCs as drug delivery systems, but also for making forward movement in the existing knowledge of involvement of major factors (tumor microenvironment, soluble signaling molecules, etc.) in the process of carcinogenesis. This capability is reliable because MSCs present a great basis for engineering and constructions of new systems to target cancers, intended to secrete therapeutic proteins in the tumor region, or for delivering of oncolytic viruses’ directly at the tumor site (targeted chemotherapy with enzyme prodrug conversion or induction of tumor cell apoptosis). MSCs as a crucial segment of the tumor surroundings and their confirmed tumor tropism, are assumed to be an open gateway for the design of promising drug delivery systems. The presented paper reviews current publications in this fieldwork, searches out the most recent patents that were published after 2012 (WO2014066122, US20140017787, WO2015100268, US20150086515), and tries to present the current progress and future prospective on the design and development in anti-cancer drug delivery systems based on MSCs.
KW - Cancer therapy
KW - Cellular therapy
KW - Drug delivery
KW - Mesenchymal stem cells
KW - Oncolytic viruses
KW - Pro-drug
KW - Target therapy
UR - http://www.scopus.com/inward/record.url?scp=84958972450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958972450&partnerID=8YFLogxK
U2 - 10.2174/1574892811666151111142721
DO - 10.2174/1574892811666151111142721
M3 - Article
C2 - 26554397
AN - SCOPUS:84958972450
SN - 1574-8928
VL - 11
SP - 98
EP - 111
JO - Recent Patents on Anti-Cancer Drug Discovery
JF - Recent Patents on Anti-Cancer Drug Discovery
IS - 1
ER -
